Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | RHOC | P08134 | 3/20 | 0.41 |
| ▸ | RHOA | P61586 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477925 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL679313 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL29593993 | 0.87 | CES2 (0.52) | CES2GAARXRARXRBRXRG | |
| SCHEMBL1792413 | 0.87 | CES2 (0.52) | CES2GAAHDAC3HDAC6RHOC | |
| SCHEMBL5227982 | 0.86 | CES2 (0.50) | CES2GAARXRARXRBRXRG | |
| SCHEMBL30253392 | 0.86 | NOTUM (0.62) | CES2GAARXRARXRBRXRG | |
| SCHEMBL477562 | 0.86 | NOTUM (0.62) | CES2GAARXRARXRBRXRG | |
| SCHEMBL12055235 | 0.86 | CES2 (0.50) | CES2GAANOTUMMAPT | |
| SCHEMBL12098032 | 0.81 | RXRA (0.47) | CES2RXRARXRBRXRGP2RX1 | |
| SCHEMBL4283632 | 0.81 | CES2 (0.50) | CES2RXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619832-A | Resveratrol-based fluorine-containing active ester compound and preparation method and application thereof | 广东工业大学 | 2024-09-10 | — | — | CN | claimed |
| CN-118598750-A | Fluorine-containing active ester compound and preparation method and application thereof | 广东工业大学 | 2024-09-06 | — | — | CN | claimed |
| CN-117123191-A | For CO 2 Adsorbed resin and preparation method thereof | 中国科学院广州能源研究所 | 2023-11-28 | — | — | CN | claimed |
| EP-4259798-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | Eisai R&D Management Co., Ltd. (JP) | 2023-10-18 | — | — | EP | claimed |
| CN-114380709-B | Synthesis method of 4-chloro-2-acylaminophenol | 西北农林科技大学 | 2023-07-21 | — | — | CN | claimed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | claimed |
| CN-103087040-B | Penicillide derivative, its preparation method and at pharmaceutical usage | FUDAN UNIVERSITY (CN) | 2015-10-28 | — | — | CN | claimed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| CN-103880877-A | Fluorine-containing solid-phase synthesis reagent and application thereof | SHANGHAI INST ORGANIC CHEM | 2014-06-25 | — | — | CN | claimed |
| EP-1125913-B1 | Preparation of 3,5-bis-(trifluormethyl)-benzoylchlorid and novel benzoylhalides: 3,5-bis-(trihalomethyl)- and 3,5-dimethyl- | BAYER AG (DE) | 2003-04-09 | — | — | EP | claimed |
| US-6420601-B2 | FREE RADICAL CHLORINATION; FLUORINATION WITH HYDROGEN FLUORIDE AND/OR ANTIMONY PENTAFLUORIDE; CONVERTING THE BENZOYL FLUORIDE TO CHLORIDE BY REACTING WITH SILICON TETRACHLORIDE IN LEWIS ACID; CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-16 | — | — | US | claimed |
| EP-1125913-A1 | Preparation of 3,5-bis-(trifluormethyl)-benzoylchlorid and novel benzoylhalides: 3,5-bis-(trihalomethyl)- and 3,5-dimethyl- | BAYER AG (DE) | 2001-08-22 | — | — | EP | claimed |
| US-20010014759-A1 | Free radical chlorination; fluorination with hydrogen fluoride and/or antimony pentafluoride; converting the benzoyl fluoride to chloride by reacting with silicon tetrachloride in lewis acid; chemical intermediates | LANXESS DEUTSCHLAND GMBH (DE) | 2001-08-16 | — | — | US | claimed |
| US-6432953-B1 | — | — | None | — | — | US | disclosed |
| CN-122079956-A | Preparation method of heterocyclic compound | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122029155-A | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-4336400-A | BRONCHODILATOR AGENTS, CARDIOVASCULAR STIMULANTS | STERLING DRUG INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014759-A1 | Free radical chlorination; fluorination with hydrogen fluoride and/or antimony pentafluoride; converting the benzoyl fluoride to chloride by reacting with silicon tetrachloride in lewis acid; chemical intermediates | SCLY, SSB, CLIC4 | CES2 836/4885GAA 2525/4885RXRA 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.